SecBot SecBot
PRESS-RELEASE ·Filed May 27, 2026

MNKD

MannKind
BULLISH
Impact 7/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The PDUFA date is May 29, 2026, two days from this release. Traders should position for binary outcome: approval would open a large new pediatric market (first needle-free insulin option in 100+ years) and likely drive significant upside. Rejection would be a major setback. The ADA data presentations provide supportive clinical context ahead of the decision.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.55
T+0 close · May 27, 2026 · via day close
Latest settled
+20.00%
T+60 · $4.26
Vs SPY
+18.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $3.55entry
  2. T+1 · 6mo ago +2.54%α +1.98% · $3.64
  3. T+5 · 6mo ago −3.38%α −4.59% · $3.43
  4. T+20 · 5mo ago +10.70%α +12.61% · $3.93
  5. T+60 · 3mo ago +20.00%α +18.12% · $4.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfaction, AID algorithm use, and gestational diabetes. The PDUFA target action date for Afrezza in pediatric patients (ages 4-17) is May 29, 2026, just two days after this press release. The data broadly support Afrezza's profile but the key catalyst is the upcoming FDA decision on pediatric approval.

Key Facts

  • PDUFA target action date for Afrezza pediatric indication (ages 4-17) is May 29, 2026
  • Nine poster presentations at ADA 2026 (June 5-8) including pediatric A1c, treatment satisfaction, AID algorithm, and gestational diabetes data
  • If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years
  • FDA accepted sBLA for review in October 2025
  • Afrezza is already approved for adults (age 18+) since June 2014 and in India and Brazil

Financial Impact

Pediatric approval would expand Afrezza's addressable patient population significantly; no specific revenue estimates provided

revenuemarket share

Risk Factors

  • FDA may issue a Complete Response Letter (CRL) on safety/efficacy grounds, particularly given the boxed warning for bronchospasm and lung function decline in adults
  • Pediatric population has additional safety considerations (lung development, hypoglycemia risk) that could delay or block approval
  • Afrezza has a history of slow commercial adoption in adults; pediatric uptake may also be gradual

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3302065

Track record

17 reports on MNKD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +19.24% at T+60 after the Jun 2, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026